RJA
PPH icon

Raymond James & Associates’s VanEck Pharmaceutical ETF PPH Stock Holding History

Raymond James & Associates’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$16.4K – 4081
2024
Q2 		$16.4K Buy
+200
New +$17.9K ﹤0.01% 3908

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FPGK
Financial Partners Group (Kansas) Overland Park, Kansas $985M AUM 29.69% 1-Year Est. Return

Raymond James & Associates's PPH Position: Q3 2024 in Review

Raymond James & Associates reduced its VanEck Pharmaceutical ETF (PPH) stake by 2.7% in Q3 2024, selling an estimated $30.8K and leaving 11,871 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

Raymond James & Associates first reported a position in PPH in Q1 2014 and has held it in 40 quarters since. The position peaked at $6.13M in Q2 2014. 142 funds tracked by Wall St. Rank hold PPH as of Q3 2024.

  • Raymond James & Associates held 11,871 shares of VanEck Pharmaceutical ETF worth $1.13M as of Q3 2024.
  • Raymond James & Associates sold 324 VanEck Pharmaceutical ETF shares in Q3 2024, an estimated $30.8K.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2616 holding.
  • Raymond James & Associates first reported a position in VanEck Pharmaceutical ETF in Q1 2014 and has held it in 40 quarters since.
  • Raymond James & Associates's VanEck Pharmaceutical ETF position peaked at $6.13M in Q2 2014.
  • 142 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.